Average Cost-Effectiveness Ratio with Censored Data

In cost-effectiveness analysis, interest could lie foremost in the incremental cost-effectiveness ratio (ICER), which is the ratio of the incremental cost to the incremental benefit of two competing interventions. The average cost-effectiveness ratio (ACER) is the ratio of the cost to benefit of an intervention without reference to a comparator. A vast literature is available for statistical inference of the ICERs, but limited methods have been developed for the ACERs, particularly in the presence of censoring. Censoring is a common feature in prospective studies, and valid analyses should properly adjust for censoring in cost as well as in effectiveness. In this article, we propose statistical methods for constructing a confidence interval for the ACER from censored data. Different methods—Fieller, Taylor, bootstrap—are proposed, and through simulation studies and data analysis, we address the performance characteristics of these methods.

[1]  J. Kupersmith,et al.  Covariate-adjusted cost–effectiveness ratios , 1999 .

[2]  Xiao-Hua Zhou,et al.  Nonparametric Statistical Methods for Cost‐Effectiveness Analyses , 2006, Biometrics.

[3]  James B. Orlin,et al.  Finding minimum cost to time ratio cycles with small integral transit times , 1993, Networks.

[4]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.

[5]  A. Briggs,et al.  Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .

[6]  Hongwei Zhao,et al.  A Study on Confidence Intervals for Incremental Cost‐Effectiveness Ratios , 2008, Biometrical journal. Biometrische Zeitschrift.

[7]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[8]  P. Wakker,et al.  Confidence intervals for cost/effectiveness ratios. , 1995, Health economics.

[9]  J. Gardiner,et al.  On Parametric Confidence Intervals for the Cost‐Effectiveness Ratio , 2001 .

[10]  Andrew R Willan,et al.  Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.

[11]  A H Briggs,et al.  Handling uncertainty in economic evaluations of healthcare interventions , 1999, BMJ.

[12]  Hongwei Zhao,et al.  On the equivalence of some medical cost estimators with censored data. , 2007, Statistics in medicine.

[13]  N. Blomqvist,et al.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1998, Statistics in medicine.

[14]  Marianne Huebner,et al.  28 The cost-effectiveness ratio in the analysis of health care programs , 2000, Bioenvironmental and public health statistics.

[15]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[16]  A. Gafni,et al.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.

[17]  A I Mushlin,et al.  The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. , 1998, Circulation.

[18]  M C Weinstein,et al.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  A. Mcguire,et al.  Estimating medical care costs under conditions of censoring. , 2004, Journal of health economics.

[21]  Milton C. Weinstein,et al.  Recommendations for Reporting Cost-effectiveness Analyses , 1996 .

[22]  A. Gafni,et al.  Information created to evade reality (ICER): things we should not look to for answers. , 2006, PharmacoEconomics.

[23]  Andrew H Briggs,et al.  A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  J. Robins,et al.  Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .

[25]  R. Obenchain Resampling and multiplicity in cost-effectiveness inference. , 1999, Journal of biopharmaceutical statistics.

[26]  Somnath Datta,et al.  The Kaplan–Meier Estimator as an Inverse-Probability-of-Censoring Weighted Average , 2001, The American statistician.

[27]  E. Feuer,et al.  Estimating medical costs from incomplete follow-up data. , 1997, Biometrics.

[28]  A H Briggs,et al.  Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. , 1999, Statistics in medicine.

[29]  C. Dewa,et al.  A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[30]  Xiao-Hua Zhou,et al.  A simulation study to compare methods for constructing confidence intervals for the incremental cost-effectiveness ratio , 2007, Health Services and Outcomes Research Methodology.

[31]  B O'Brien,et al.  Statistical analysis of cost effectiveness data. , 1999, The Journal of rheumatology.

[32]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[33]  E. Laska,et al.  The usefulness of average cost‐effectiveness ratios , 1997 .

[34]  Anthony O'Hagan,et al.  On estimators of medical costs with censored data. , 2004, Journal of health economics.

[35]  D. Lin,et al.  Linear regression analysis of censored medical costs. , 2000, Biostatistics.

[36]  E. C. Fieller SOME PROBLEMS IN INTERVAL ESTIMATION , 1954 .

[37]  M Meisner,et al.  Statistical inference for cost-effectiveness ratios. , 1997, Health economics.

[38]  J. Baron,et al.  Incremental and Average Cost‐Effectiveness Ratios: Will Physicians Make a Distinction? , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[39]  E. S. Pearson,et al.  On the Problem of the Most Efficient Tests of Statistical Hypotheses , 1933 .

[40]  Joseph C. Gardiner,et al.  Estimating medical costs from a transition model , 2008, 0805.2496.

[41]  A. Briggs,et al.  Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. , 1997, Health Economics.

[42]  D Polsky,et al.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.

[43]  D. Horvitz,et al.  A Generalization of Sampling Without Replacement from a Finite Universe , 1952 .

[44]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[45]  S. Stearns,et al.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.

[46]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[47]  H. Bang Medical cost analysis: application to colorectal cancer data from the SEER Medicare database. , 2005, Contemporary clinical trials.

[48]  Yijian Huang,et al.  Cost analysis with censored data. , 2009, Medical care.

[49]  Anastasios A. Tsiatis,et al.  Estimating medical costs with censored data , 2000 .

[50]  E. S. Pearson,et al.  On the Problem of the Most Efficient Tests of Statistical Hypotheses , 1933 .

[51]  H Zhao,et al.  On Estimating Medical Cost and Incremental Cost‐Effectiveness Ratios with Censored Data , 2001, Biometrics.

[52]  Daniel H. Wagner Nonlinear Functional Versions of the Neyman–Pearson Lemma , 1969 .

[53]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.